Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Contemporary immunomodulatory therapy for multiple sclerosis.

R A Rudick1

  • 1Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. rudickr@ccf.org

Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society
|January 5, 2002
PubMed
Summary

Multiple sclerosis (MS) is now manageable with five approved drugs. Early diagnosis and treatment are key, as therapies like interferon beta and glatiramer acetate show effectiveness in modifying MS progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple Sclerosis Performance Test: validation of self-administered neuroperformance modules.

European journal of neurology·2020
Same author

Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2015
Same author

Simple MRI metrics contribute to optimal care of the patient with multiple sclerosis.

AJNR. American journal of neuroradiology·2014
Same author

Prescribing recommendations for interferon-Beta in multiple sclerosis.

CNS drugs·2013
Same author

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.

Neurology·2011
Same author

Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.

Multiple sclerosis (Houndmills, Basingstoke, England)·2011

Area of Science:

  • Neurology
  • Immunology

Background:

  • Multiple sclerosis (MS) was historically viewed as unmanageable.
  • Recent advancements have led to effective disease-modifying therapies.

Purpose of the Study:

  • To review the current landscape of disease-modifying treatments for MS.
  • To highlight the importance of early diagnosis and intervention.

Main Methods:

  • Review of regulatory-approved medications for MS.
  • Summary of clinical trial findings on treatment efficacy.
  • Discussion of treatment strategies for different MS subtypes.

Main Results:

  • Five drugs are approved for MS treatment: three interferon beta preparations (Avonex, Betaseron, Rebif), glatiramer acetate (Copaxone), and mitoxantrone (Novantrone).

Related Experiment Videos

  • Interferon beta and glatiramer acetate are effective in relapsing-remitting MS and show potential in secondary progressive MS.
  • Mitoxantrone is approved for secondary progressive and progressive relapsing MS.

    • Conclusions:

    • MS is a manageable condition with available therapies.
    • Early treatment initiation is crucial for optimal outcomes.
    • Treatment effectiveness may decrease with disease advancement.